Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Reaffirms FY 2013 Guidance


Wednesday, 24 Apr 2013 06:30am EDT 

Eli Lilly And Co reaffirmed fiscal 2013 guidance and expects fiscal 2013 earnings per share (EPS) to be in the range of $4.10 to $4.25 on a reported basis, or $3.82 to $3.97 on a non-GAAP basis. The company still anticipates fiscal 2013 revenue of between $22.6 billion and $23.4 billion. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $3.90 on revenue of $22.9 billion for fiscal 2013. 

Company Quote

70.16
0.42 +0.60%
24 Dec 2014